Hib vaccine conjugate - sanofi pasteur

Drug Profile

Hib vaccine conjugate - sanofi pasteur

Alternative Names: ActHIB; DF-098

Latest Information Update: 04 Nov 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi pasteur
  • Developer Sanofi Pasteur
  • Class Haemophilus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilus infections

Most Recent Events

  • 02 Aug 2010 sanofi pasteur-Daiichi Sankyo Vaccine Co. agrees to terminate its shareholders agreement on October 31, 2010
  • 30 Jul 2010 sanofi pasteur reaches an agreement to acquire sanofi pasteur-Daiichi Sankyo Vaccine
  • 19 Dec 2008 Launched for Haemophilus infections in Japan (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top